RT Journal Article SR Electronic T1 Regulatory de novo mutations underlying intellectual disability JF medRxiv FD Cold Spring Harbor Laboratory Press SP 2022.11.14.22279410 DO 10.1101/2022.11.14.22279410 A1 Matias G De Vas A1 Fanny Boulet A1 Shweta S Joshi A1 Myles G Garstang A1 Tahir N. Khan A1 Goutham Atla A1 David Parry A1 David Moore A1 Inês Cebola A1 Shuchen Zhang A1 Wei Cui A1 Anne K Lampe A1 Wayne W Lam A1 Genomics England Research Consortium A1 Jorge Ferrer A1 Madapura M Pradeepa A1 Santosh S Atanur YR 2022 UL http://medrxiv.org/content/early/2022/11/17/2022.11.14.22279410.abstract AB The genetic aetiology of a major fraction of patients with intellectual disability (ID) remains unknown. De novo mutations (DNMs) in protein-coding genes explain up to 40% of cases, but the potential role of regulatory DNMs is still poorly understood. We sequenced 63 whole genomes from 21 ID probands and their unaffected parents (trio). Additionally, we analysed 30 previously sequenced genomes from exome-negative ID probands. We found that regulatory DNMs were selectively enriched in fetal brain-specific and human-gained enhancers. DNM-containing enhancers were associated with genes that show preferential expression in the pre-frontal cortex, have been previously implicated in ID or related disorders, and exhibit intolerance to loss of function mutations. Moreover, we found that highly interacting regulatory regions from intermediate progenitor cells of the developing human cortex were strongly enriched for ID DNMs. Furthermore, we identified recurrently mutated enhancer clusters that regulate genes involved in nervous system development (CSMD1, OLFM1, and POU3F3). The majority of the DNMs from ID probands showed allele-specific enhancer activity when tested using luciferase assay. Using CRISPR-mediated mutation and editing of epigenomic marks, we show that regulatory elements harbouring DNMs indeed function as enhancers and DNMs at regulatory elements affect the expression of putative target genes. Our results, therefore, provide new evidence to indicate that DNMs in fetal brain-specific enhancers play an essential role in the aetiology of ID.Competing Interest StatementThe authors have declared no competing interest.Funding StatementNational Institute for Health Research (NIHR) Imperial Biomedical Research Centre Wellcome Trust Institute Strategic Support Wellcome Trust Medical Research Council European Research Council Advanced Grant UKRI/MRC Barts charityAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The ethics approval for this study was obtained from Multi-centre Research Ethics Committees (MRECs), Scotland. The ethics application has been approved by the Scottish MREC with application number 05/MRE00/74 (Scottish MREC 05/MRE00/74).I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe whole-genome sequence (WGS) data is not publicly available because it contains information that could compromise research participant privacy/consent. However, WGS data and variant calls that support the findings of this study are available on request from the corresponding author [S.S.A.].ASDAutism Spectrum DisorderATAC-seqAssay for Transposase-Accessible Chromatin with high-throughput sequencingBWABurrows-Wheeler AlignerccREscandidate cis-Regulatory ElementsChIP-seqChromatin ImmunoPrecipitation sequencingCNVCopy Number VariantCRISPRClustered Regularly Interspaced Short Palindromic RepeatsCRISPRiCRISPR interferenceDDDDeciphering Developmental DisorderDNADeoxyribonucleic AcidDNMDe novo MutationeNexcitatory NeuronsENCODEEncyclopedia of DNA ElementsExACExome Aggregation ConsortiumFBSEFetal Brain-Specific EnhancersGATKGenome Analysis ToolkitGELGenomics England LimitedGoNLGenome of NetherlandsGQGenotype QualityGWASGenome Aide Association StudiesH3K27acacetylation of histone H3 at lysine 27H3K4me1mono-methylation of histone H3 at lysine 4H3K4me3tri-methylation of histone H3 at lysine 4HEK293THuman Embryonic Kidney 293THGEHuman Gain EnhancersHi-CChromosome Conformation CaptureHPOHuman Phenotype OntologyIDIntellectual DisabilityiNinterNeuronsIndelsInsertions and deletionsIPCIntermediate Progenitor CellsLoFLoss of FunctionPCHi-CPromoter Capture Hi-CPLAC-seqProximity ligation-assisted ChIP-SeqpLIprobability of Loss of function IntolerancePTVProtein-Truncating VariantsRGRadical GliaSFARISimons Foundation Autism Research InitiativeSID4xfour copies of Sin3 Interacting DomainSNVSingle Nucleotide VariantTADTopologically Associated DomainsTFTranscription FactorsTFBSTF Binding SitesTPMTags Per MillionVCFVariant Call FormatWGSWhole-Genome Sequencing